Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer.

Zeng-Fu ShangAnwen LiuXinchen SunLuying LiuYaqun ZhuTao ZhangJianhui JiaShisheng TanJunxin WuXin WangJuying ZhouJialin YangChen ZhangHongyan ZhangYuanyuan ZhaoGang Cai Wei ZhangFan XiaJuefeng WanHui ZhangLijun ShenSanJun CaiZhen Zhang

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

Adding irinotecan guided by UGT1A1 genotype to capecitabine-based neoadjuvant chemoradiotherapy significantly increased complete tumor response in Chinese patients.

Keyphrases

phase iii
locally advanced
rectal cancer
double blind
open label
neoadjuvant chemotherapy
placebo controlled
clinical trial
phase ii study
phase ii
squamous cell carcinoma
radiation therapy
study protocol
lymph node
cross sectional
metastatic breast cancer